Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the effectiveness of three treatment arms that
are designed to improve survival in patients with non-small cell lung cancer. Eligible
subjects could be randomized to four (4) cycles of chemotherapy followed by immunotherapy, or
immunotherapy followed by chemotherapy, or four cycles of chemotherapy plus immunotherapy.